5alpha9alphaDihydroxymatrine | 72362-00-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 羽扇豆生物碱
• 英文名称: 5alpha9alphaDihydroxymatrine
• 英文别名: (1R,2R,9R,15S,17R)-9,15-dihydroxy-7,13-diazatetracyclo[7.7.1.02,7.013,17]heptadecan-6-one
• CAS: 72362-00-6
• 化学式: C₁₅H₂₄N₂O₃
• 分子量: 280.36
• InChiKey: BYQQDLUCCAZYJO-PGKPSXLWSA-N

物化性质

• 沸点：
  487.2±45.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  64
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• GENE NETWORK-BASED METHOD FOR CONFIRMING DRUG ACTION
  申请人：Tsinghua University

  公开号：EP2369493A1

  公开（公告）日：2011-09-28

  The invention provides a network-based method for confirming drug action(drug effect, synergistic reaction). The method be carried out by mapping a first drug genes/gene products subset and a second genes/gene products subset in a gene network. The second genes/gene products subset can be a second drug genes/gene products subset or a biological process genes/gene products subset. The invention also provides a tool for pre-clinical drug screening.

  本发明提供了一种基于网络的确认药物作用（药物效应、协同反应）的方法。该方法通过在基因网络中绘制第一药物基因/基因产物子集和第二基因/基因产物子集来实现。第二基因/基因产物子集可以是第二药物基因/基因产物子集，也可以是生物过程基因/基因产物子集。本发明还为临床前药物筛选提供了一种工具。
• Method of using geranium oil and sophora root extracts as a supporting composition in cancer treatments
  申请人：MediGreen Biotechnology Inc.

  公开号：US20030134003A1

  公开（公告）日：2003-07-17

  The present invention relates to a method of use involving the administration of the herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, to mammalian animals undergoing cancer treatments that would induce the bone marrow suppression side effect, such as chemotherapy and radiation therapy. The composition can take on the form of an oil capsule, tablets, pills, and pastes etc. to be administered orally at specific dosages. The composition can also take on the form of an injection to be administered intravenously and intraperitoneally at specific dosages. The administration can be made before and or after the cancer treatment.

  本发明涉及一种使用方法，包括向正在接受会诱发骨髓抑制副作用的癌症治疗（如化疗和放疗）的哺乳动物施用由天竺葵油和槐属植物根提取物组成的草药组合物。组合物可以是油胶囊、片剂、丸剂和膏剂等形式，按特定剂量口服给药。组合物还可以采用注射剂的形式，按特定剂量静脉注射或腹腔注射。可以在癌症治疗之前或之后给药。
• Methods of use of herbal compositions
  申请人：Fong A.T. Andy

  公开号：US20050025823A1

  公开（公告）日：2005-02-03

  The present invention relates to herbal composition and methods of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, particularly S. flavescenes and S. tonkinensis, to humans and other mammalian animals with gastric ulcers induced by H. pylori infection. The same composition is shown to be able to eradicate H. pylori in vitro. The invention also relates to a composition comprising citronellol and extracts from roots of Sophora plants. The present invention further relates to the use of citronellol to inhibit gastric ulcers. The invention also relates to the use of the same composition to inhibit the enzymatic activity of Na + /K + -ATPase to strengthen heart muscle contractions and prevent heart failure.

  本发明涉及草药组合物和草药组合物的施用方法，该草药组合物由天竺葵油和槐属植物根的提取物组成。 槐属植物根部的提取物、 特别是 S. flavescenes 和 S. tonkinensis、 对人类和其他因幽门螺杆菌诱发胃溃疡的哺乳动物的影响 幽门螺杆菌 感染的人类和其他哺乳动物的胃溃疡。同样的成分还能根除 幽门螺杆菌 体外根除幽门螺杆菌。本发明还涉及一种由香茅醇和槐根提取物组成的组合物。 槐 植物根部的提取物。本发明还涉及使用香茅醇抑制胃溃疡。本发明还涉及使用相同的组合物抑制 Na + /K + -ATP酶的酶活性，以加强心肌收缩和预防心力衰竭。
• US7387806B2
  申请人：——

  公开号：US7387806B2

  公开（公告）日：2008-06-17
• [EN] METHOD OF USING GERANIUM OIL AND SOPHORA ROOT EXTRACTS AS A SUPPORTING COMPOSITION IN CANCER TREATMENTS<br/>[FR] METHODE PERMETTANT D'UTILISER DES EXTRAITS D'HUILE DE GERANIUM ET DE RACINE DE SOPHORA COMME COMPOSITION DE CONFORT DANS DES TRAITEMENTS DU CANCER
  申请人：MEDIGREEN BIOTECHNOLOGY INC

  公开号：WO2004035075A1

  公开（公告）日：2004-04-29

  The present invention relates to a method of use involving the administration of the herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, to mammalian animals undergoing cancer treatments that would induce the bone marrow suppression side effect, such as chemotherapy and radiation therapy. The composition can take on the form of an oil capsule, tablets, pills, and pastes etc. to be administered orally at specific dosages. The composition can also take on the form of an injection to be administered intravenously and intraperitoneally at specific dosages. The administration can be made before and or after the cancer treatment. In one embodiment, the composition is administered intraperitoneally.